• Blog
  • Overt Hepatic Encephalopathy Market Report

    Overt Hepatic Encephalopathy Market Report

    Overt Hepatic Encephalopathy Market Report
    Report code - SRHL277 Delivery - 2 Weeks
    Get Free Sample |
    Play Audio
    Listen
    Global Overt Hepatic Encephalopathy Market, Dynamics, and Market Analysis
    See more...

    Impact of COVID-19 on Overt Hepatic Encephalopathy Market

    Covid-19 has impacted the market dynamics, competition, and global...

    See more...

    Impact of COVID-19 on Overt Hepatic Encephalopathy Market

    Covid-19 has impacted the market dynamics, competition, and global supply chain. The revenues have gone down in 2020 and may resume an uptrend gradually from 2021. Companies optimizing their operation and strategy will sustain and beat the competition.

    Note: The summary below might not have included insights on covid impact since we have large number of reports.

    Market Insights

    The Global Overt Hepatic Encephalopathy Market is expected to grow from USD 71.3 million in 2020 to USD 130.6 million by 2026 at a CAGR of over 10.8% during the forecast period.

    Figure: Global Overt Hepatic Encephalopathy Market Size, 2020-2026 (USD Million)

    Overt-Hepatic-Encephalopathy-Market-Forecast

    Wish to receive more information about this study? Click here to get a free sample.

    What is Overt Hepatic Encephalopathy?

    Hepatic encephalopathy is a brain disorder that most commonly occurs in people having chronic liver disease. Its complications could be dysfunction of the brain and may include impaired memory, intellectual impairment, personality changes, and loss of consciousness (coma). Overt hepatic encephalopathy is associated with obvious, outward signs and symptoms in the affected individuals.

    Key Players

    Key players operating in the global Overt Hepatic Encephalopathy Market are-

    • Alfa Wassermann S.P.A (Italy),
    • Rebiotix Inc. (The U.S),
    • Cosmo Pharmaceuticals S.P.A (Italy),
    • Spherium Biomed S.L (Spain),
    • Horizon Pharma Plc (Ireland),
    • Umecrine Cognition AB (Sweden),
    • Ocera Therapeutics Inc. (The U.S),
    • Mallinckrodt Pharmaceuticals (UK),
    • Kannalife Sciences Inc. (The U.S),
    • Bausch Health Companies Inc. (The U.S),
    • ASKA Pharmaceutical Co., Ltd (Japan), and
    • Norgine BV (Netherlands).

    Market Dynamics

    The growth of the global overt hepatic encephalopathy market is primarily driven by the rising number of people having cirrhosis disease.

    • Cirrhosis is a chronic liver damage illness that can result in scarring and liver failure.
    • Increasing consumption of alcohol has resulted in an increased incidence of liver disease among people.
    • This further can lead to overt hepatic encephalopathy illness and thus, drive the market growth.
    • Growing emphasis on the development of advanced solutions by the market players is likely to propel the market growth at a significant rate during the review period.

    Segment Analysis

    Treatment Trends

    Based on treatment, the market has been segmented into lactulose, antibiotics, probiotics, liver transplantation, and others. The lactulose segment accounted for the largest market share in 2020. The segment growth can be attributed to its ability to reduce ammonia production in the intestine by creating an aggressive for the bad microbes in the intestine.

    Regional Trends

    Geographically, the market in North America accounted for the largest market share in 2020 and is expected to continue its dominance over the forecast period owing to an increasing number of people suffering from cirrhosis. For instance, around 5.5 million people in the U.S are affected by cirrhosis and approximately 70% of them are likely to develop symptoms of overt hepatic encephalopathy. The market in the Asia-Pacific region is projected to register the fastest growth during the review period on account of the rising number of people suffering from chronic liver diseases.

    COVID-19 Impact on Global Overt Hepatic Encephalopathy Market

    The covid-19 outbreak is projected to have a long-term impact on the growth of overt hepatic encephalopathy as people suffering from cirrhosis disease require intense preventive care which was affected by the due spread of coronavirus. It affected the process developed to provide good care to the patients.

    Critical Questions Answered in the Report

    • What are the key trends in the global overt hepatic encephalopathy market?
    • How the market (and its various sub-segments) has grown in the last five years and what would be the growth rate in the next five years?
    • What is the impact of COVID-19 on the global overt hepatic encephalopathy market?
    • What are the key strategies adopted by the major vendors to lead in the global overt hepatic encephalopathy market?
    • What is the market share of the top vendors?

    Want to know the full scope of the report? Register Here

    Target Audience

    Here is the list of the group of customers that the Global Overt Hepatic Encephalopathy market hopes to have the greatest opportunity to convert-

    • Overt hepatic encephalopathy manufacturers
    • Overt hepatic encephalopathy suppliers
    • Overt hepatic encephalopathy distributors
    • Organizations
    • Government bodies

    Custom Research: Stratview research offers custom research services across sectors. In case of any custom research requirement related to market assessment, competitive benchmarking, sourcing and procurement, target screening, and others, please send your inquiry at [email protected].

    Frequently Asked Questions (FAQs)

    The overt hepatic encephalopathy market size is expected to reach USD 130.6 million in the foreseeable future.

    Alfa Wassermann S.P.A (Italy), Rebiotix Inc. (The U.S), Cosmo Pharmaceuticals S.P.A (Italy), Spherium Biomed S.L (Spain), Horizon Pharma Plc (Ireland), Umecrine Cognition AB (Sweden), Ocera Therapeutics Inc. (The U.S), Mallinckrodt Pharmaceuticals (UK), Kannalife Sciences Inc. (The U.S), Bausch Health Companies Inc. (The U.S), ASKA Pharmaceutical Co., Ltd (Japan) and Norgine BV (Netherlands) are among the key players in the overt hepatic encephalopathy market.

    The overt hepatic encephalopathy market is expected to witness an impressive growth of 10.8% CAGR in the foreseeable future.

    North America is expected to remain dominant in the overt hepatic encephalopathy market during the forecast period.

    Asia-pacific is expected to register the fastest growth in the overt hepatic encephalopathy market in the coming years.

    The lactulose segment accounted for the largest share in the overt hepatic encephalopathy market in 2020.

    Overt hepatic encephalopathy manufacturers, Overt hepatic encephalopathy suppliers, Overt hepatic encephalopathy distributors, Organizations, Government bodies are the target audience in the overt hepatic encephalopathy market.

    •